Tavist and Transient ischaemic attack - a phase IV clinical study of FDA data

Summary:

Transient ischaemic attack is reported as a side effect among people who take Tavist (clemastine fumarate), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Dimetapp, and have Nasopharyngitis.

The phase IV clinical study analyzes which people have Transient ischaemic attack when taking Tavist. It is created by eHealthMe based on reports of 2,141 people who have side effects when taking Tavist from the FDA, and is updated regularly.

What is Tavist?

Tavist has active ingredients of clemastine fumarate. eHealthMe is studying from 2,149 Tavist users. Check the latest studies of Tavist.

What is Transient ischaemic attack?

Transient ischaemic attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)) is found to be associated with 1,586 drugs and 1,643 conditions by eHealthMe. Check the latest studies of Transient ischaemic attack.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

2,141 people reported to have side effects when taking Tavist.
Among them, 67 people (3.13%) have Transient ischaemic attack.

Could Tavist cause Transient ischaemic attack?

Among these 67 people:

How long have people been on Tavist when they have Transient ischaemic attack? *

What is the gender of people who have Transient ischaemic attack when taking Tavist? *

female: 67.16 %
male: 32.84 %

What is the age of people who have Transient ischaemic attack when taking Tavist? *

What are other drugs people take besides Tavist? *

What are other side effects people have besides Transient ischaemic attack? *

Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 36 people, 53.73%
Memory Loss: 9 people, 13.43%
Heart Attack: 7 people, 10.45%
Haemorrhagic Stroke (stroke caused by the rupture of a blood vessel in the brain): 7 people, 10.45%
Chest Pain: 5 people, 7.46%
Cerebral Atrophy (decrement in size of brain): 5 people, 7.46%
Speech Impairment (Adult) (inability to speak (adult)): 5 people, 7.46%
Hypoaesthesia (reduced sense of touch or sensation): 5 people, 7.46%
Embolic Stroke (stroke due to obstruction due to an embolus): 4 people, 5.97%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 4 people, 5.97%

What are the existing conditions these people have? *

Nasopharyngitis (inflammation of the nasopharynx): 6 people, 8.96%
Sinus Congestion (blockage of sinus): 5 people, 7.46%
Hypersensitivity: 1 person, 1.49%
High Blood Pressure: 1 person, 1.49%
Diabetes: 1 person, 1.49%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 1 person, 1.49%

* Approximation only. Some reports may have incomplete information.

Do you take Tavist and have Transient ischaemic attack?

- Check whether Transient ischaemic attack is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tavist:

Tavist (2,149 reports)

Browse all side effects of Tavist:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Transient ischaemic attack:

Transient ischaemic attack (1,586 drugs)

Browse all the conditions that are associated with Transient ischaemic attack:

Transient ischaemic attack (1,643 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on clemastine fumarate (the active ingredients of Tavist) and Tavist (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.